Endocrine therapy is an important way of breast cancer treatment. Patients with estrogen receptor or progesterone receptor positive breast cancer should use endocrine therapy after surgery, as follows: 1. The main forms of drug therapy used in premenopausal women are tamoxifen drugs, toremifene drugs, etc. Endocrine therapy for postmenopausal women with breast cancer mainly includes AI agents, such as exemestane, anastrozole, letrozole, etc.; 2. Another way of endocrine therapy is ovarian function depot, and the main ways of depot are drug depot and surgical depot. The main methods of endocrine therapy are drug depot and surgical depot. The more commonly used drugs in clinical practice are OFS drugs, including leuprolide and goserelin. Surgical ovarian function depot endocrine therapy, before the invention of drug ovarian function depot, mainly through surgical ovarian function depot, including surgical removal of ovaries, laparoscopic oophorectomy, to achieve ovarian depot endocrine therapy effect; 3. SERM class drugs, which belong to estrogen and progesterone receptor antagonists, including fulvestrant, are mainly used in recent years in patients with mid to late stage hormone receptor positive breast cancer. Hormone receptor positive with metastasis and recurrence are mainly treated by endocrine therapy with the SERM class drug fulvestrant. In summary, endocrine treatment modalities mainly include premenopausal use of moxifen and toremifene, postmenopausal use of mainly AI drugs such as exemestane, letrozole, anastrozole, or SERM drugs such as fulvestrant, and ovarian function depot, including surgical depot and OFS drug depot.